BRPI9917760B8 - método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada - Google Patents

método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada

Info

Publication number
BRPI9917760B8
BRPI9917760B8 BRPI9917760A BR9917760A BRPI9917760B8 BR PI9917760 B8 BRPI9917760 B8 BR PI9917760B8 BR PI9917760 A BRPI9917760 A BR PI9917760A BR 9917760 A BR9917760 A BR 9917760A BR PI9917760 B8 BRPI9917760 B8 BR PI9917760B8
Authority
BR
Brazil
Prior art keywords
uricase
isolating
purified
solution
tetrameric form
Prior art date
Application number
BRPI9917760A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9917760B1 (pt
Inventor
L Williams David
G P Saifer Mark
R Sherman Merry
S Hershfield Michael
J Kelly Susan
Original Assignee
Univ Duke
Mountain View Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Mountain View Pharmaceuticals Inc filed Critical Univ Duke
Publication of BR9917760B1 publication Critical patent/BR9917760B1/pt
Publication of BRPI9917760B8 publication Critical patent/BRPI9917760B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI9917760A 1998-08-06 1999-08-02 método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada BRPI9917760B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13039298A 1998-08-06 1998-08-06
US09/130,132 1998-08-06
PCT/US1999/017514 WO2000007629A2 (en) 1998-08-06 1999-08-02 Peg-urate oxidase conjugates and use thereof

Publications (2)

Publication Number Publication Date
BR9917760B1 BR9917760B1 (pt) 2014-11-25
BRPI9917760B8 true BRPI9917760B8 (pt) 2021-05-25

Family

ID=22444494

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9917760A BRPI9917760B8 (pt) 1998-08-06 1999-08-02 método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada
BRPI9912974A BRPI9912974B8 (pt) 1998-08-06 1999-08-02 conjugados de peg-urato oxidase e seu uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI9912974A BRPI9912974B8 (pt) 1998-08-06 1999-08-02 conjugados de peg-urato oxidase e seu uso

Country Status (13)

Country Link
EP (1) EP1100542B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP5183836B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR100614212B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU770014B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (2) BRPI9917760B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ303751B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HU226294B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL141220A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ509595A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL220873B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (3) RU2246318C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW570981B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2000007629A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CN1896231B (zh) 1998-08-06 2012-09-05 山景药品公司 分离四聚体尿酸氧化酶的方法
RU2246318C2 (ru) * 1998-08-06 2005-02-20 Маунтэн Вью Фармасьютикэлз, Инк. Конъюгаты peg-уриказы и их использование
NZ509633A (en) 1998-08-06 2003-04-29 Univ Duke A recombinant chimeric PEG-uricase with a long circulatory life and reduced immunogenicity
AU2006203252B8 (en) * 2000-02-10 2009-06-18 Duke University Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CA2404737C (en) 2000-04-03 2010-06-29 Santen Pharmaceutical Co., Ltd. Drug delivering substance containing polyalkylene glycol and phospholipid covalently bonded to drug
CA2413201A1 (en) * 2000-06-28 2002-01-03 Merck & Co., Inc. Treatment for cardiovascular disease
AU2002345938A1 (en) 2001-06-28 2003-03-03 Mountain View Pharmaceuticals, Inc. Polymer stabilized proteinases
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
CN1849141A (zh) 2003-05-12 2006-10-18 阿费麦克斯公司 用于聚(乙二醇)修饰的肽的间隔臂部分
BRPI0411172A (pt) 2003-05-12 2006-07-18 Affymax Inc peptìdeo, dìmero de peptìdeo, seu uso e composição farmacêutica
JP2008505119A (ja) * 2004-06-30 2008-02-21 ネクター セラピューティクス アラバマ，コーポレイション 高分子−第ｉｘ因子部分の抱合体
CA2604399A1 (en) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. Variant forms of urate oxidase and use thereof
CN101194016B (zh) 2005-04-11 2012-09-05 萨文特医药公司 尿酸氧化酶的变体形式及其用途
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US8841333B2 (en) 2005-05-09 2014-09-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating nephrolithiasis
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
ES2532804T3 (es) * 2006-04-12 2015-03-31 Crealta Pharmaceuticals Llc Purificación de proteínas con tensioactivo catiónico
JP4890132B2 (ja) * 2006-07-20 2012-03-07 東洋紡績株式会社 ウリカーゼの比活性を向上させる方法、および比活性の向上した改変型ウリカーゼ
RU2382048C1 (ru) * 2008-12-25 2010-02-20 Общество С Ограниченной Ответственностью "Фармапарк" Лекарственное средство на основе модифицированного интерферона альфа с пролонгированным терапевтическим действием
SG10201408480RA (en) 2009-06-25 2015-02-27 Crealta Pharmaceuticals Llc Methods for preventing or predicting infusion reactions or antibody-mediated loss of response, by monitoring serum uric acid levels during pegylated uricase therapy
US9107912B2 (en) 2010-09-10 2015-08-18 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
WO2013151638A1 (en) 2012-04-06 2013-10-10 Indus Pharmaceuticals, Inc. Novel compositions of combinations of non-covalent dna binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment
SG10201910522TA (en) 2015-05-15 2020-01-30 Medimmune Llc Improved uricase sequences and methods of treatment
CN105412942B (zh) * 2015-12-23 2019-02-26 沈阳三生制药有限责任公司 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
CA3055936A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CN112980808B (zh) * 2019-12-12 2024-10-29 深圳迈瑞生物医疗电子股份有限公司 尿酸酶、及其制备方法和用途
CA3197108A1 (en) 2020-11-03 2022-05-12 Ilya Ruderfer Modified uricase and uses thereof
CN114438047B (zh) * 2020-11-05 2024-11-22 重庆派金生物科技有限公司 制备聚乙二醇修饰的尿酸氧化酶的方法
CN114438048B (zh) * 2020-11-05 2024-10-22 重庆派金生物科技有限公司 尿酸氧化酶制剂及其应用
CA3211023A1 (en) 2021-02-10 2022-08-18 Oriental Yeast Co., Ltd. Uricase activator and uric acid measurement reagent
CN114181917B (zh) * 2022-02-14 2022-06-03 潍坊华卓生物科技有限公司 一种改造尿酸酶、基因序列、制备方法及应用
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1529675A (fr) * 1967-03-29 1968-06-21 Applic Biochimiques Soc Et Urate oxydase à haute activité et sa préparation
US3616231A (en) * 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6031472B2 (ja) * 1978-12-14 1985-07-22 協和醗酵工業株式会社 酸性ウリカ−ゼ
JPS55135590A (en) * 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
JPS57192435A (en) * 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
JPS6255079A (ja) * 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
NZ509633A (en) * 1998-08-06 2003-04-29 Univ Duke A recombinant chimeric PEG-uricase with a long circulatory life and reduced immunogenicity
RU2246318C2 (ru) * 1998-08-06 2005-02-20 Маунтэн Вью Фармасьютикэлз, Инк. Конъюгаты peg-уриказы и их использование
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates

Also Published As

Publication number Publication date
IL183948A (en) 2010-11-30
PL202799B1 (pl) 2009-07-31
TW570981B (en) 2004-01-11
RU2004104953A (ru) 2005-07-27
JP5183836B2 (ja) 2013-04-17
KR100488848B1 (ko) 2005-05-11
HUP0103003A2 (hu) 2001-11-28
AU770014B2 (en) 2004-02-12
WO2000007629A3 (en) 2000-06-08
EP1100542A2 (en) 2001-05-23
KR20040088585A (ko) 2004-10-16
BRPI9912974B1 (pt) 2015-08-25
PL220873B1 (pl) 2016-01-29
CZ2001317A3 (cs) 2001-07-11
AU5251599A (en) 2000-02-28
HU226294B1 (en) 2008-08-28
IL141220A (en) 2007-09-20
IL141220A0 (en) 2002-03-10
PL346224A1 (en) 2002-01-28
KR20010072287A (ko) 2001-07-31
KR100614212B1 (ko) 2006-08-21
PL383331A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2002-01-28
WO2000007629A2 (en) 2000-02-17
RU2278680C2 (ru) 2006-06-27
NZ509595A (en) 2004-02-27
BR9912974A (pt) 2001-05-08
IL183948A0 (en) 2007-10-31
RU2006107111A (ru) 2007-09-20
JP2002522399A (ja) 2002-07-23
RU2349341C2 (ru) 2009-03-20
HU228916B1 (en) 2013-06-28
BRPI9912974B8 (pt) 2021-05-25
RU2246318C2 (ru) 2005-02-20
JP2013039139A (ja) 2013-02-28
JP2009254376A (ja) 2009-11-05
HUP0103003A3 (en) 2006-04-28
EP1100542B1 (en) 2005-06-22
BR9917760B1 (pt) 2014-11-25
JP5291235B2 (ja) 2013-09-18
CZ303751B6 (cs) 2013-04-24
JP5290901B2 (ja) 2013-09-18

Similar Documents

Publication Publication Date Title
BRPI9917760B8 (pt) método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada
AU5624699A (en) Use of 5ht-6 antagonists
ATE483797T1 (de) Harnsäureoxidase
BR0010428A (pt) Uso de compostos
MXPA05011223A (es) Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas 5-htif.
BR9910251A (pt) Estimulação hematopoiética
MXPA02007639A (es) Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva.
SG161247A1 (en) Variant forms of urate oxidase and use thereof
NZ504258A (en) Exendin 3 and 4 agonist compounds for the treatment of diabetes
PT1112275E (pt) Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase
WO2003011211A3 (en) Peg-modified uricase
BR0211442A (pt) Cepas de bifidobacterium probióticas
BR0008176A (pt) Derivados anti-convulsivantes úteis no tratamento de cefaléias em cacho
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
DE69943205D1 (de) Peg-uricase Konjugate und Verwendung davon
WO2002103103A3 (en) Fluorine-containing compounds and polymers derived therefrom
WO2001066553A3 (en) Novel aryl fructose-1,6-bisphosphatase inhibitors
BR0311161A (pt) Método de tratamento de diabetes
WO2002018361A3 (en) Compounds having activity as inhibitors of cytochrome p450rai
AU2002338852A1 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO2002074344A3 (en) Peg-conjugates of hgt-nk4
WO1999058098A8 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
WO2002064816A3 (en) Multiple determinants for metabolic phenotypes
WO2004069781A3 (en) 7-(3,5-diisopropylphenyl) heptatrienoic acid derivatives having serum glucose reducing activity
WO2001007644A3 (en) Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)

Free format text: EXTINCAO DEFINITIVA - ART. 78 INCISO IV DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/11/2014, OBSERVADAS AS CONDICOES LEGAIS.

B24E Patent annual fee: resolution cancelled

Free format text: REFERENTE AO DESPACHO 24.8 PUBLICADO NA RPI 2289 DE 18/11/2014.

B15K Others concerning applications: alteration of classification

Ipc: C12N 9/06 (2006.01), A61K 47/60 (2017.0

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/08/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 02/08/2019